Asia-Pacific Multicancer Screening Market - Analysis and Forecast, 2023-2032
Introduction to Asia-Pacific (APAC) Multicancer Screening Market
As of 2022, the Asia-Pacific multicancer screening market was valued at $0.27 billion and is expected to attain a value of $1.40 billion by 2032. The rising incidence of cancer and growing use of liquid biopsy testing are anticipated to fuel market expansion for multicancer screening in Asia-Pacific.
Market Introduction
The market for multicancer screening in Asia-Pacific (APAC) is expected to develop significantly as the area concentrates on improving healthcare infrastructure and tackling the increased incidence of different malignancies. The practice of multicancer screening, which is the simultaneous detection of numerous cancer types by sophisticated diagnostic techniques, is becoming more and more popular throughout Asia-Pacific as people become more aware of the critical role that early detection plays in enhancing treatment outcomes. The market is being pushed by increasing initiatives for cancer prevention and control, an aging population, and technical breakthroughs in screening technologies. The multicancer screening market is growing as a result of governments and healthcare organizations in the Asia-Pacific area placing a strong emphasis on the adoption of comprehensive cancer screening programs. The market for APAC multicancer screening is expected to grow as demand increases for more accessible and precise cancer diagnosis.
Market Segmentation
Segmentation 1: by Country
China
Japan
India
Australia
South Korea
Rest-of-Asia-Pacific
In 2021, China was the leading contributor to the Asia-Pacific multicancer screening market, with a market share of 32.64%. Japan is the second-largest contributor to the Asia-Pacific multicancer screening market.
How can this report add value to an organization?
Product/Innovation Strategy: The report considers multicancer screening kit/panel and assay product-based companies. The industry is seeing constant development and product launches with new and innovative upgrades. Additionally, new discoveries of specific biomarkers related to various cancer types are increasing researchers' trust in multicancer sequencing.
Growth/Marketing Strategy: The key components in multicancer screening are the kits and the related technologies for sample analysis. The advancements in new analysis methods like liquid biopsy are influencing the growth of this market. Additionally, the discovery of biomarkers and other genes for various diseases is helping panel manufacturers curate precise kits and assays for multicancer screening of various cancer types.
Competitive Strategy: The key players in the Asia-Pacific multicancer screening market have been analyzed and profiled in the study, consisting of most product-based companies, as well as a few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the Asia-Pacific multicancer screening market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts, analyzing company coverage, product portfolio, and market penetration.
Some of the prominent names established in this market are:
Burning Rock DX
Genecast Biotechnology Co., Ltd
Konica Minolta, Inc. (Ambry Genetics.)
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 3-5 business days to complete the report upon order confirmation.
- 1 Markets
- 1.1 Product Definition
- 1.2 Inclusion and Exclusion Criteria
- 1.3 Market Scope
- 1.3.1 Scope of the Study
- 1.3.2 Key Questions Answered in the Report
- 1.4 Research Methodology
- 1.4.1 Asia-Pacific Multicancer Screening Market: Research Methodology
- 1.4.2 Data Sources
- 1.4.3 Market Estimation Model
- 1.4.4 Criteria for Company Profiling
- 2 Market Overview
- 2.1 Market Overview
- 2.2 Multicancer Screening Workflow Analysis
- 2.3 Market Footprint and Growth Potential
- 2.4 Future Potential
- 2.5 COVID-19 Impact on the Market
- 3 Industry Insights
- 3.1 Patent Analysis
- 3.1.1 Patent Filing Trend
- 3.1.2 Patent Analysis (by Country)
- 3.1.3 Patent Analysis (by Region)
- 3.2 Reimbursement Scenario
- 3.3 Supply Chain Analysis
- 3.4 Pricing Analysis (by Test Type)
- 4 Market Dynamics
- 4.1 Overview
- 4.2 Impact Analysis
- 4.3 Market Drivers
- 4.3.1 Early Detection of Cancer Leads to Higher Survival Chances and Better Treatment
- 4.3.2 Increasing Popularity of Liquid Biopsy Leading to Easier Screening
- 4.3.3 Reduced Treatment Cost Due to Earlier Cancer Detection
- 4.4 Market Challenges
- 4.4.1 Lack of Awareness about the Multicancer Screening Tests
- 4.4.2 Too Costly to be Used as Preventive Care
- 4.5 Market Opportunities
- 4.5.1 Robust Pipeline of Multicancer Screening Tests Poised to Revolutionize Cancer Diagnosis
- 4.5.2 New Biomarkers being Discovered Regularly
- 5 Competitive Landscape
- 5.1 Key Strategies and Developments
- 5.1.1 Mergers and Acquisitions
- 5.1.2 Synergistic Activities
- 5.1.3 Product Launches and Upgradations
- 5.1.4 Funding and Expansion
- 5.2 Market Share Analysis (2022)
- 5.3 Growth-Share Analysis (2022)
- 5.3.1 Growth-Share Analysis (by Technology)
- 6 Asia-Pacific
- 6.1 Overview
- 6.2 Asia-Pacific
- 6.2.1 China
- 6.2.2 Japan
- 6.2.3 India
- 6.2.4 Australia
- 6.2.5 South Korea
- 6.2.6 Rest-of-Asia-Pacific
- 7 Markets - Company Profiles
- 7.1 Overview
- 7.2 Market Value Chain of Multicancer Screening Market
- 7.3 Multicancer Screening Ecosystem Active Players
- 7.4 Burning Rock DX
- 7.4.1 Company Overview
- 7.4.2 Role of Burning Rock DX in the Asia-Pacific Multicancer Screening Market
- 7.4.3 Key Competitors of the Company
- 7.4.4 Business Strategies
- 7.4.5 Analyst Perspective
- 7.5 Genecast Biotechnology Co., Ltd
- 7.5.1 Company Overview
- 7.5.2 Role of Genecast Biotechnology Co., Ltd in the Asia-Pacific Multicancer Screening Market
- 7.5.3 Key Competitors of the Company
- 7.5.4 Analyst Perspective
- 7.6 Konica Minolta, Inc. (Ambry Genetics.)
- 7.6.1 Company Overview
- 7.6.2 Role of Konica Minolta, Inc. (Ambry Genetics.) in the Asia-Pacific Multicancer Screening Market
- 7.6.3 Key Competitors of the Company
- 7.6.4 Financials
- 7.6.5 Analyst Perspective
- List of Figures
- Figure 1: Asia-Pacific Multicancer Screening Market, $Billion, 2022 and 2032
- Figure 2: Share of Asia-Pacific Multicancer Screening Market (by Test Type), $Billion, 2021 and 2032
- Figure 3: Share of Asia-Pacific Multicancer Screening Market (by Sample), $Billion, 2021 and 2032
- Figure 4: Share of Asia-Pacific Multicancer Screening Market (by Cancer Type), $Billion, 2021 and 2032
- Figure 5: Share of Multicancer Screening Market (by Region), 2022
- Figure 6: Asia-Pacific Multicancer Screening Market Segmentation
- Figure 7: Asia-Pacific Multicancer Screening Market: Research Methodology
- Figure 8: Primary Research Methodology
- Figure 9: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 10: Top-Down Approach (Segment-Wise Analysis)
- Figure 11: Multicancer Screening Workflow, End User Perspective
- Figure 12: Multicancer Screening Workflow, Laboratory Technician Perspective
- Figure 13: Asia-Pacific Multicancer Screening Market, $Billion, 2021-2032
- Figure 14: COVID-19 Impact
- Figure 15: Asia-Pacific Multicancer Screening Market, Patent Analysis (by Year), January 2020-December 2022
- Figure 16: Multicancer Screening Market, Patent Analysis (by Country), January 2020-December 2022
- Figure 17: Multicancer Screening Market, Patent Analysis (by Region), January 2020-December 2022
- Figure 18: Supply Chain Analysis of the Multicancer Screening Market
- Figure 19: Asia-Pacific Multicancer Screening Market Dynamics
- Figure 20: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, 2010-2019 (%)
- Figure 21: Liquid Biopsy vs. Tissue Biopsy
- Figure 22: Liquid Biopsy Clinical Trials (by Cancer Types), Share (%), 2023
- Figure 23: Out-of-Pocket Costs for Complete Treatment by Cancer Type and Stage Among Insured Patient, ($)
- Figure 24: Lead-Time Bias in Cancer Screening
- Figure 25: Screened vs. Non-Screened Cancer Patients per 1,000,000 Incidence Rate (50-79 Years)
- Figure 26: Multicancer Early Detection Tests + Usual Care Screening Costs vs. only Usual Care Screening Costs
- Figure 27: Share of Key Developments and Strategies, January 2020-January 2023
- Figure 28: Synergistic Activities Share (by Company), January 2020- January 2023
- Figure 29: Product Launches and Upgradations (by Company), January 2020-January 2023
- Figure 30: Market Share Analysis for Asia-Pacific Multicancer Screening Market, $Billion, 2022
- Figure 31: Growth-Share Analysis of the Asia-Pacific Multicancer Screening Market (by Technology), 2022
- Figure 32: Multicancer Screening Market Snapshot (by Region), $Billion, 2022
- Figure 33: Multicancer Screening Market (by Region), $Billion, 2021-2032
- Figure 34: Asia-Pacific Multicancer Screening Market, $Billion, 2021-2032
- Figure 35: Asia-Pacific Multicancer Screening Market Share (by Country), $Million, 2021-2032
- Figure 36: China Multicancer Screening Market, $Million, 2021-2032
- Figure 37: Japan Multicancer Screening Market, $Million, 2021-2032
- Figure 38: India Multicancer Screening Market, $Million, 2021-2032
- Figure 39: Australia Multicancer Screening Market, $Million, 2021-2032
- Figure 40: South Korea Multicancer Screening Market, $Million, 2021-2032
- Figure 41: Rest-of-Asia-Pacific Multicancer Screening Market, $Million, 2021-2032
- Figure 42: Multicancer Screening Market, Total Number of Companies Profiled
- Figure 43: Multicancer Screening Market: Value Chain
- Figure 44: Burning Rock DX: Product Portfolio
- Figure 45: Genecast Biotechnology Co., Ltd: Product Portfolio
- Figure 46: Konica Minolta, Inc. (Ambry Genetics.): Product Portfolio
- Figure 47: Konica Minolta, Inc. (Ambry Genetics.): Overall Financials, $Million, 2019-2021
- Figure 48: Konica Minolta, Inc. (Ambry Genetics.): Revenue (by Segment), $Million, 2019-2021
- Figure 49: Konica Minolta, Inc. (Ambry Genetics.): Revenue (by Region), $Million, 2019-2021
- Figure 50: Konica Minolta, Inc. (Ambry Genetics.): R&D Expenditure, $Million, 2019-2021
- List of Tables
- Table 1: Impact Analysis of Market Drivers, Challenges, and Opportunities on the Asia-Pacific Multicancer Screening Market
- Table 2: Technological Trends in Asia-Pacific Multicancer Screening Market
- Table 3: Average Prices of Multicancer Screening Kits Calculation
- Table 4: Likert Scale
- Table 5: Impact Analysis of Market Drivers
- Table 6: Impact Analysis of Market Challenges
- Table 7: Five-Year Survival Rates for Different Cancers at Different Stages
- Table 8: Top Multicancer Screening Tests and Their Costs ($)
- Table 9: Asia-Pacific Multicancer Screening Market, Pipeline Tests
- Table 10: Cancers and Their Most Common Biomarker Tests
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook